From Wall Street Journal (Asia Edition) | 11 July 2013.
New Hope for Acne Sufferers
Quantec presents results of clinical trial at New Zealand Dermatological Society Annual Meeting
HAMILTON, New Zealand, July 11, 2013 /PRNewswire-iReach/ — New Zealand-based dairy biotechnology company, Quantec Ltd, presented the results of its US clinical trial on acne to dermatologists at the New Zealand Dermatological Society Annual Meeting in Coolum, Australia on July 11-12.
In the clinical trial conducted at a clinical research facility in California, USA and completed in February 2013, Quantec’s patented complex of bioactive milk proteins – called IDP® – was the active ingredient in a specially formulated skin cream that went head-to-head in a double blind study against a premium, US-based clinical brand of acne treatment cream (containing 2% salicylic acid plus retinal).
At the conclusion of the 42-day trial involving 84 subjects, both the premium brand of acne treatment cream and the IDP®-basedcream showed statistically equivalent results in terms of total reduction in acne lesions.
The IDP®-basedcream, however, also showed a major improvement of over 52% in reduction of redness and inflammation.
As part of the clinical assessment, the IDP®-basedcream also passed specific testing for use on subjects with sensitive skin, making it the superior performer of the two products and ideal for users with hyper-reactive and sensitive skin.
Founder and Managing Director of Quantec Ltd, Dr Rod Claycomb, explains that, “IDP® is a unique and naturally derived complex of bio-proteins. These bio-proteins have unique properties, which make them very powerful against certain types of disease-causing bacteria which leave the natural and beneficial bacteria of the skin largely unaffected.
“By leaving these natural and beneficial bacteria active on the skin, IDP® creates a perfect scenario for treatment and management of acne. In addition, the IDP® bio-proteins signal directly to inflamed tissues and cells to quell the inflammatory response. IDP® contains what we refer to as ‘Triple-A’ activity – antibacterial, anti-inflammatory and antioxidant.”
Dr Claycomb said Quantec was founded on the value that all its products are proven through science and, as such, it was important to the company to unveil IDP® and its efficacy as an acne treatment to dermatologists first prior to developing and launching a commercial acne product.
“Quantec is a company committed to developing high-value bioactives from natural products, which are backed with solid science. It has taken our research and development team seven years to create IDP® and now prove its efficacy as an acne treatment.
“Therefore, it was important to us to detail the results of our clinical trial and gain the backing of industry-leading dermatologists prior to a commercial product launch.”
IDP® clinical results at a glance
- Study compared IDP®-basedcream with premium, US-based clinical brand of acne treatment cream
- Statistically equivalent results in terms of total reduction in acne lesions
- IDP®-basedcream showed over 52% improvement in reduction of redness and inflammation
- IDP®-basedcream passed specific testing for use on subjects with sensitive skin
About Quantec Ltd
Based at the Waikato Innovation Park in Hamilton, New Zealand, Quantec is a company specialising in the discovery and commercialisation of high-value bioactives from natural products. Quantec discovered and patented its novel milk fraction, comprised of native immune defense proteins (IDP®), that has proven antimicrobial and anti-inflammatory properties. www.idpbio.com
From Quantec Ltd | 20 June 2013.
Quantec announces a major Japanese distribution deal
Hamilton, New Zealand – New Zealand-based dairy biotechnology company, Quantec Ltd, announced recently that it has signed a distribution and supply agreement with a major Japanese specialty ingredients company, Kanematsu Chemicals Corporation. Kanematsu will distribute Quantec’s patented complex of bioactive milk proteins called IDP® throughout Japan.
In a deal that is expected to extend over a number of years, the distribution agreement provides Quantec further expansion into the Asian market and provides Kanematsu with access to a unique New Zealand dairy-based bioactive protein ingredient for inclusion into Japanese functional foods and human health products.
“Japanese consumers have always looked very favorably on New Zealand dairy products and we expect the agreement between Quantec and Kanematsu to further build on this customer perception of quality and innovation,” according to James Groenhart, Business Development Manager of Kanematsu New Zealand Ltd, who is a spokesman for the Japanese company.
While the patented complex of bioactive milk proteins called IDP® is not marketed directly in North America, it is however available for supply from New Zealand and is approved for use in dietary supplements. In addition the Company has completed a number of clinical studies in the United States on IDP®,over the past 5 years. These studies have investigated the complementary effect of IDP® on the human innate immune system (also known as non-specific immune system or “first line of defense”) and the ability for IDP® to correctly control the size or amplitude of the immune response after injury or infection.
Founder and Managing Director of Quantec Ltd, Dr Rod Claycomb explains that, “IDP® is a unique ingredient naturally derived from fresh milk. It contains what we refer to as ‘Triple-A’ activity – antibacterial, anti-inflammatory and antioxidant. These bioactive proteins, which tend to resist much of the digestive process; work synergistically to destroy pathogenic bacteria, dampen the inflammatory response that often follows the infection or tissue damage and then completes the cycle by helping to promote the healing process. We have conducted studies using IDP® on subjects with systemic inflammation from arthritis, acne infections of the face and bacterial halitosis of the oral cavity, every time IDP® was shown to have a significant clinical advantage.”
Founded in 2007, Quantec is unlike many other dairy-based companies in New Zealand who manufacture and market dairy commodities like milk powder, Quantec is focused on the discovery and commercialization of high-value bioactive compounds from milk.
About Quantec Ltd
Based at the Waikato Innovation Park in Hamilton, New Zealand, Quantec is a company specializing in the discovery and commercialization of high-value bioactives from natural products. Quantec discovered and patented its novel milk fraction, comprised of native immune defense proteins (IDP®), that has proven antimicrobial and anti-inflammatory properties. www.quantec.co.nz
Pharmacy Today | 10 July 2012.
Launch into China a mint of a deal for milk protein innovator
Quantec Limited today announced it has signed a major deal to sell its patented milk protein ingredient – IDP® – to Auckland-based NZ New Paradise.
NZ New Paradise has secured exclusive rights to the unique ingredient for use in oral care and throat care confectionery products manufactured in New Zealand and exported to China.
NZ New Paradise’s first IDP-based product will be a mint to fight halitosis, launched under its existing Purel brand. The company also plans to capitalise on IDP’s proven ability to kill bad bacteria in the mouth and reduce inflammation by manufacturing a flavoured chewable tablet for Chinese children to boost their oral health.
General Manager of Auckland-based NZ New Paradise, Lavinia Huang, says, “Purel sees IDP-based products as a springboard into the Chinese market for oral health products that address the cause of bad breath and boost people’ immune systems.
“Purel and Quantec share a desire to deliver high-quality, safe and healthy products manufactured in New Zealand into the Chinese market.
“Our products will initially be launched at a major baby and infant products expo in Shanghai from 17-19 July and then released progressively to other cities and regions including: Beijing, Hunan, Hubei, Jiangsu and Zhejiang. They will be sold online as well as in baby care shops,” explains Ms Huang.
Based at the Waikato Innovation Park in Hamilton, New Zealand, Quantec is a company specialising in the discovery and commercialisation of high-value bioactives from natural products. In 2006, Quantec discovered and patented its novel milk fraction, comprised of native immune defense proteins (IDP®), that has proven anti-microbial and anti-inflammatory properties.
Founder and Managing Director, Dr Rod Claycomb, explains that IDP “is a unique ingredient in that it is naturally derived from fresh milk. Plus, when used in an oral care product, IDP targets and kills organisms responsible for bad odour but leaves healthy mouth organisms unharmed.”
Quantec and NZ New Paradise have worked together extensively to develop some unique formulations, scope the Chinese market and test consumers’ attitudes toward IDP-based products.
Dr Claycomb says, “We’ve been working with NZ New Paradise for over a year to test the Chinese market and prepare for market introduction. As a result of time spent in-market, Quantec projects China has the potential to be a $2 million market for us.
“Chinese consumers look very favourably on New Zealand dairy products and we expect Purel’s mint and chewable tablets to fulfil a real market need.
“Several years ago we were fortunate to secure New Zealand Trade and Enterprise funding for export growth, which has been invaluable in helping us to get to this stage. That funding allowed us to engage international marketing consultants, publicise Quantec and IDP in China and attend Chinese tradeshows.”
The terms of the deal between Quantec and New Zealand New Paradise remain confidential.
Stuff.co.nz | 10 July 2012.
Milk protein product to fight bad breath in China
© Fairfax NZ News
Hamilton biotechnology company Quantec has signed a deal that could open up a $2 million-a-year oral and throat-care market in China for its patented milk protein ingredient.
Quantec managing director Rod Claycomb said Auckland-based NZ New Paradise had bought exclusive rights to the milk protein ingredient, patented as IDP, for use in oral-care and throat-care confectionery products made in New Zealand and exported to China.
NZ New Paradise’s first IDP-based product would be a mint to fight bad breath, launched under its Purel brand, he said.
The company also planned to build on IDP’s proven ability to kill bad bacteria in the mouth and reduce inflammation by manufacturing a flavoured chewable tablet for Chinese children to improve oral health. The products will be launched at a major baby and infant products expo in Shanghai on July 17-19, which Claycomb will attend.
The products will be introduced progressively to other cities and regions in China, including Beijing, Hunan, Jiangsu and Zhejiang. They will be sold online and in baby shops.
European and North American companies were also interested in IDP for similar uses, Claycomb said. A New Zealand launch is not planned.
Quantec had been developing the milk protein for six years. It had made some “modest” sales of IDP but the deal with New Paradise was the first significant sale. Quantec had been working with NZ New Paradise for a year, testing the Chinese market and preparing for the market launch.
CosmeticsDesign.com | 10 October 2009.
By Katie Bird
Anti-microbial milk proteins could help alleviate acne, psoriasis and halitosis
Proteins in milk that form part of the cow’s natural protection against milking related infections can be formulated into anti-microbial cosmetics and oral care products, according to manufacturer Quantec. The New Zealand-based company has been working on the Immune Defence Proteins (IDP) for three years and is now ready to launch the ingredients onto the skin care and supplements market.
Rod Claycomb, managing director of the company, explained how the proteins form part of the cow’s own defence system. “After milking, cows are quite prone to bacterial infection of the mammary gland called mastitis. This suite of proteins is nature’s own way of helping to protect the cow,” he said. According to Claycomb, there are applications for the proteins in both human and animal health.
Currently the company is preparing for the launch of the ingredient onto the oral care market at the food and supplements show Supply Side West in Las Vegas next month. “IDP is good at nailing the bad bacteria in the mouth that lead to halitosis and gum disease,” Claycomb explained.
In order to extend the time in contact with the oral cavity, chewing gum or lozenges would be the best delivery method, he said. In addition, Quantec is launching the ingredient onto the topical skin care market where the anti-microbial mode of action is similar but the anti-inflammatory and anti-oxidant properties of the proteins are equally important.
Potential applications for skin care include anti-acne formulations, products proposing relief from psoriasis and dandruff, as well as anti-fungal systems such as those fighting against yeast infections like candida albicans and athletes foot. Although Quantec will primarily focus on the US cosmetics and supplements market, the launch is global and the company is seeking international clients. For the human health applications the company proposes to stay within the cosmetics and supplements market and not venture into the pharmaceutical ‘treatment space’; however, Quantec hopes its animal health applications will result in a registered animal pharmaceutical.
Animal health applications
IDP’s role in animal health centre’s on developing an antibiotic-free treatment for mastitis. This could be a significant earner for the company as the demand for non-antibiotic treatments is impressive. Currently when a cow is receiving antibiotics its milk cannot be mixed into the rest of the milk supply, which is costly for the farmer, explained Claycomb, and if there is unintentional mixing the farmer is liable to a heavy fine. As IDP is found naturally in the milk itself – treatment would simply involve adding extra IDP – milk from cows treated with it would not need to be separated, he explained.